JP2014501510A5 - - Google Patents

Download PDF

Info

Publication number
JP2014501510A5
JP2014501510A5 JP2013540387A JP2013540387A JP2014501510A5 JP 2014501510 A5 JP2014501510 A5 JP 2014501510A5 JP 2013540387 A JP2013540387 A JP 2013540387A JP 2013540387 A JP2013540387 A JP 2013540387A JP 2014501510 A5 JP2014501510 A5 JP 2014501510A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid residue
binding protein
terminal capping
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013540387A
Other languages
English (en)
Japanese (ja)
Other versions
JP6173216B2 (ja
JP2014501510A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/071084 external-priority patent/WO2012069655A2/en
Publication of JP2014501510A publication Critical patent/JP2014501510A/ja
Publication of JP2014501510A5 publication Critical patent/JP2014501510A5/ja
Application granted granted Critical
Publication of JP6173216B2 publication Critical patent/JP6173216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013540387A 2010-11-26 2011-11-25 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール Active JP6173216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10192711 2010-11-26
EP10192711.9 2010-11-26
PCT/EP2011/071084 WO2012069655A2 (en) 2010-11-26 2011-11-25 Improved n-terminal capping modules for designed ankyrin repeat proteins

Publications (3)

Publication Number Publication Date
JP2014501510A JP2014501510A (ja) 2014-01-23
JP2014501510A5 true JP2014501510A5 (OSRAM) 2014-11-27
JP6173216B2 JP6173216B2 (ja) 2017-08-02

Family

ID=43858162

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013540387A Active JP6173216B2 (ja) 2010-11-26 2011-11-25 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール
JP2013540386A Active JP6105479B2 (ja) 2010-11-26 2011-11-25 血清アルブミンに結合する設計リピートタンパク質
JP2016211658A Pending JP2017048216A (ja) 2010-11-26 2016-10-28 血清アルブミンに結合する設計リピートタンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013540386A Active JP6105479B2 (ja) 2010-11-26 2011-11-25 血清アルブミンに結合する設計リピートタンパク質
JP2016211658A Pending JP2017048216A (ja) 2010-11-26 2016-10-28 血清アルブミンに結合する設計リピートタンパク質

Country Status (13)

Country Link
US (5) US9221892B2 (OSRAM)
EP (3) EP2643349B1 (OSRAM)
JP (3) JP6173216B2 (OSRAM)
KR (3) KR101782790B1 (OSRAM)
CN (3) CN103403024B (OSRAM)
AU (2) AU2011333665B2 (OSRAM)
BR (3) BR112013012786B1 (OSRAM)
CA (2) CA2818990C (OSRAM)
DK (1) DK2643349T3 (OSRAM)
ES (2) ES2758352T3 (OSRAM)
PL (1) PL2643349T3 (OSRAM)
RU (2) RU2625882C2 (OSRAM)
WO (2) WO2012069654A1 (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
KR101782790B1 (ko) 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
US10568934B2 (en) 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
KR20150023957A (ko) * 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
AU2013331763B2 (en) * 2012-10-15 2018-02-15 Universitat Zurich Bispecific HER2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP3444278A1 (en) 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
EP3167395B1 (en) 2014-07-07 2020-09-02 Yeda Research and Development Co., Ltd. Method of computational protein design
SG11201707606RA (en) * 2015-04-02 2017-10-30 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
NZ751689A (en) 2016-09-22 2021-07-30 Molecular Partners Ag Recombinant binding proteins and their use
EP3535397B1 (en) * 2016-11-01 2022-01-05 Arrowhead Pharmaceuticals, Inc. Alpha-v beta-6 integrin ligands and uses thereof
WO2018165046A1 (en) 2017-03-07 2018-09-13 Igc Bio, Inc. A computational pipeline for antibody modeling and design
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3768833A1 (en) 2018-03-22 2021-01-27 Charité - Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
US12448458B2 (en) 2018-06-15 2025-10-21 Universität Bern Ligands to light or its receptor LTßR for use in haematologic malignancies
BR112021005670A2 (pt) 2018-10-08 2021-06-22 Universität Zürich polipeptídeos tetraméricos de ligação a her2
EP3883919A1 (en) 2018-11-21 2021-09-29 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
US20220088144A1 (en) 2019-01-11 2022-03-24 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
WO2020207771A1 (en) 2019-04-10 2020-10-15 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
BR112021024231A2 (pt) 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas de ligação fap recombinantes e uso da mesma
WO2020245171A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
US20200385488A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
US20220332845A1 (en) 2019-09-05 2022-10-20 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
EP4073093A2 (en) 2019-12-11 2022-10-19 Molecular Partners AG Recombinant peptide-mhc complex binding proteins and their generation and use
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
EP4132578A1 (en) 2020-04-06 2023-02-15 Universität Zürich Artc1 ligands for cancer treatment
AU2021267411A1 (en) 2020-05-06 2022-12-08 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
US20240279309A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
CA3189257A1 (en) 2020-08-18 2022-02-24 Universitat Zurich A cd25-biased anti-il-2 antibody
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US11981710B2 (en) * 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
EP4263608A1 (en) 2020-12-16 2023-10-25 Molecular Partners AG Recombinant cd3 binding proteins and their use
US20240108746A1 (en) 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs
WO2022171831A1 (en) 2021-02-11 2022-08-18 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
EP4043481A1 (en) * 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
WO2022190018A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なDARPinに基づく多重特異性T細胞エンゲージャ
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のDARPinに基づくCD33エンゲージャ
EP4323388B1 (en) 2021-04-16 2025-01-29 Athebio AG N-terminal capping modules of ankyrin repeat domains
AU2022322029A1 (en) 2021-08-05 2024-02-15 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
JP2024529079A (ja) 2021-08-05 2024-08-01 イムノス セラピューティクス アーゲー 発現量が増加した改変型hla-b57
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
CA3262553A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
EP4573106A2 (en) 2022-08-16 2025-06-25 Athebio AG Variants of ankyrin repeat domains
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
WO2024133013A1 (en) 2022-12-19 2024-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Means and methods to target endogenous condensates
WO2024165671A1 (en) 2023-02-08 2024-08-15 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2024251742A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd2 binding proteins and their use
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2024251695A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd47 binding proteins and their use
WO2025008519A1 (en) 2023-07-05 2025-01-09 Universität Bern Il-1ra blockers for treatment and prevention of sepsis
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025163083A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recobminant dll3 binding proteins and their use
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025202503A1 (en) 2024-03-28 2025-10-02 Universität Zürich Extracellular vesicles carrying cancer specific splice variants

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
NZ511699A (en) 1998-12-02 2003-02-28 Phylos Inc DNA-protein fusions and uses thereof
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP5291279B2 (ja) * 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PT2316852E (pt) 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
DK1902131T3 (da) 2005-07-08 2010-03-01 Univ Zuerich Fag-display under anvendelse af cotranslational translokation af fusionspolypeptider
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20100034194A1 (en) * 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20100129368A9 (en) 2006-10-11 2010-05-27 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
JP2010539915A (ja) 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
US20110262964A1 (en) * 2008-03-19 2011-10-27 Hugues Bedouelle Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
WO2012060748A1 (en) * 2010-11-03 2012-05-10 Telefonaktiebolaget Lm Eriksson (Publ) A radio base station and a method therein
KR101782790B1 (ko) * 2010-11-26 2017-09-28 몰리큘라 파트너스 아게 혈청 알부민에 결합하는 설계된 반복 단백질
KR20140039203A (ko) 2011-04-29 2014-04-01 얀센 바이오테크 인코포레이티드 Il4/il13 결합 반복 단백질 및 용도
KR20150023957A (ko) 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
SG11201707606RA (en) * 2015-04-02 2017-10-30 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin

Similar Documents

Publication Publication Date Title
JP2014501510A5 (OSRAM)
RU2013128895A (ru) Улучшенные n-терминальные кэппинг модули для сконструированных белков с анкириновым повтором
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
JP2010065037A5 (OSRAM)
JP2015212284A5 (OSRAM)
JP2010539915A5 (OSRAM)
JP2010534684A5 (OSRAM)
JP2012126742A5 (OSRAM)
JP2013507132A5 (OSRAM)
JP2014525439A5 (OSRAM)
JP2014224126A5 (OSRAM)
JP2009529509A5 (OSRAM)
JP2010519252A5 (OSRAM)
JP2015525217A5 (OSRAM)
JP2013048638A5 (OSRAM)
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
JP2016500250A5 (OSRAM)
JP2010166916A5 (OSRAM)
JP2012095652A5 (OSRAM)
JP2009527226A5 (OSRAM)
JP2005120106A5 (OSRAM)
RU2018137842A (ru) Агонисты рецепторов глюкагона/glp-1 для лечения ожирения
JP2012082206A5 (OSRAM)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2015521206A5 (OSRAM)